David Spencer, MD
Urology · Ocean Springs, MSNPI 1386842755
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,427 of the $4,042 with a category attached, or 84.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations.
Across 124 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$944
- Tolmar Pharmaceuticals, Inc.$498
- Astellas Pharma US Inc$406
- Dendreon Pharmaceuticals LLC$261
- Pfizer$173
- Boston Scientific$172
- plus $2K from 33 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Food & beverage$3,42785%
- Education$61515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $944 |
| Tolmar Pharmaceuticals, Inc. | 2 | $498 |
| Astellas Pharma US Inc | 15 | $406 |
| Dendreon Pharmaceuticals LLC | 6 | $261 |
| Pfizer | 9 | $173 |
| Boston Scientific | 2 | $172 |
| Urogen Pharma, Inc. | 8 | $168 |
| Medtronic | 4 | $119 |
| Stryker | 1 | $106 |
| Coloplast | 3 | $91 |
| Endo USA, Inc. | 4 | $87 |
| Endo Pharmaceuticals Inc. | 4 | $85 |
| Covidien LP | 1 | $83 |
| Bayer | 4 | $77 |
| Progenics Pharmaceuticals, Inc. | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Davol Inc. | 2 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $55 |
| AbbVie(2 entities) | 3 | $43 |
| Teleflex LLC | 2 | $43 |
| Tolmar, Inc. | 2 | $42 |
| Steris Corporation | 1 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $29 |
| Antares Pharma, Inc. | 1 | $28 |
| Merck | 1 | $26 |
| Accord Healthcare, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 2 | $24 |
| Axonics, Inc. | 2 | $24 |
| Bard Access Systems, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Blue Earth Diagnostics | 1 | $19 |
| Hollister Incorporated | 1 | $19 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $18 |
| Neotract Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,042 in reported general payments places this provider in the 55th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 14 | $212,225 |
| OrgovyxRelugolix | 64 | $170,264 |
| MyrbetriqMirabegron | 73 | $46,778 |
| GemtesaVibegron | 11 | $12,035 |
| Tamsulosin Hcl | 588 | $8,330 |
| Oxybutynin Chloride ErOxybutynin Chloride | 230 | $3,495 |
| Tolterodine Tartrate ErTolterodine Tartrate | 25 | $2,743 |
| Estradiol | 32 | $2,286 |
| CefuroximeCefuroxime Axetil | 224 | $2,142 |
| Solifenacin Succinate | 37 | $1,467 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 91 | $1,248 |
| Finasteride | 110 | $1,145 |
| Silodosin | 13 | $765 |
| NitrofurantoinNitrofurantoin Macrocrystal | 40 | $659 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $944 | $212,22514 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $69 | $182,29975 claims |
| Astellas Pharma US IncMyrbetriq | $406 | $46,77873 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 94 urology providers in Mississippi.
Other urology in Ocean Springs
- Mark LyellOcean Springs$4K
- David OwensOcean Springs$4K
- Ian CoateOcean Springs$3K
- Guy ShoafOcean Springs$2K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.